结直肠癌中免疫检查点CD47的研究进展

Research progress of immune checkpoint CD47 in colorectal cancer

肿瘤免疫治疗在结直肠癌(colorectal cancer,CRC)患者治疗中的成功使得肿瘤疫苗、单抗、过继T细胞疗法(adoptive cell transfer therapy,ACT)治疗、免疫检查点抑制剂等免疫治疗方式引起广泛关注。目前,应用前景较好的免疫治疗就是包括程序性死亡受1/程序性死亡配体1(programmed death receptor 1/programmed death ligand 1,PD-1/PD-L1)和细胞毒性T淋巴细胞相关抗原4(cytotoxic T lymphocyte antigen 4,CTLA-4)抑制剂在内的免疫检查点抑制剂。PD-1/PD-L1和CTLA-4抑制剂仅在失配修复缺陷的CRC患者中显示出较好的疗效,而对于其他类型的CRC,靶向CD47-SIRPα免疫检查点抑制剂将是未来治疗热点。文章就近年CRC免疫治疗及免疫检查点CD47的研究进展进行综述。

The success of tumor immunotherapy in the treatment of colorectal cancer(CRC)patients has caused widespread attention to immunotherapy methods such as tumor vaccine treatment,monoclonal antibody,adoptive T cell therapy(ACT),immune checkpoint inhibitor treatment,etc.At present,immune checkpoint inhibitors including programmed death receptor 1/programmed death ligand 1(PD-1/PD-L1)and cytotoxic T lymphocyte antigen 4(CTLA-4),have a good application prospect.PD-1/PD-L1 and CTLA-4 inhibitors only show good efficacy in CRC patients with mismatched repair defects.For other types of CRC,targeting CD47-SIRPαimmune checkpoint inhibitor will be a hot spot in future treatment.This review summarizes the research progress of immunotherapy and immune checkpoint CD47 therapy on CRC.